These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27965044)

  • 21. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
    Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
    Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aminoadamantanes for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.
    MacLeod A; Daly C; Khan I; Vale L; Campbell M; Wallace S; Cody J; Donaldson C; Grant A
    Cochrane Database Syst Rev; 2001; (3):CD003234. PubMed ID: 11687058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.
    Ferreira-González I; Busse JW; Heels-Ansdell D; Montori VM; Akl EA; Bryant DM; Alonso-Coello P; Alonso J; Worster A; Upadhye S; Jaeschke R; Schünemann HJ; Permanyer-Miralda G; Pacheco-Huergo V; Domingo-Salvany A; Wu P; Mills EJ; Guyatt GH
    BMJ; 2007 Apr; 334(7597):786. PubMed ID: 17403713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet therapy and anticoagulation in patients with hypertension.
    Griffin G
    Am Fam Physician; 2005 Mar; 71(5):897-9. PubMed ID: 15768617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement.
    Austin PC; Fine JP
    Stat Med; 2017 Apr; 36(8):1203-1209. PubMed ID: 28102550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding competing risks: a simulation point of view.
    Allignol A; Schumacher M; Wanner C; Drechsler C; Beyersmann J
    BMC Med Res Methodol; 2011 Jun; 11():86. PubMed ID: 21639902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis?
    Troendle JF; Leifer ES; Kunz L
    Stat Med; 2018 Apr; ():. PubMed ID: 29707832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing points-based risk-scoring systems in the presence of competing risks.
    Austin PC; Lee DS; D'Agostino RB; Fine JP
    Stat Med; 2016 Sep; 35(22):4056-72. PubMed ID: 27197622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.
    Rauch G; Rauch B; Schüler S; Kieser M
    World J Cardiol; 2015 Jan; 7(1):1-5. PubMed ID: 25632312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The exposure odds ratio in nested case-control studies with competing risks.
    Flanders WD; Louv WC
    Am J Epidemiol; 1986 Oct; 124(4):684-92. PubMed ID: 3752062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing risks and the clinical community: irrelevance or ignorance?
    Koller MT; Raatz H; Steyerberg EW; Wolbers M
    Stat Med; 2012 May; 31(11-12):1089-97. PubMed ID: 21953401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal treatment regimes for competing risk data using doubly robust outcome weighted learning with bi-level variable selection.
    He Y; Kim S; Kim MO; Saber W; Ahn KW
    Comput Stat Data Anal; 2021 Jun; 158():. PubMed ID: 33994608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methodologic Issues When Estimating Risks in Pharmacoepidemiology.
    Edwards JK; Hester LL; Gokhale M; Lesko CR
    Curr Epidemiol Rep; 2016 Dec; 3(4):285-296. PubMed ID: 28824834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Competing risk and heterogeneity of treatment effect in clinical trials.
    Kent DM; Alsheikh-Ali A; Hayward RA
    Trials; 2008 May; 9():30. PubMed ID: 18498644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THE MOUSE INFECTIVITY TITRATION OF INFLUENZA VIRUS.
    Lauffer MA; Miller GL
    J Exp Med; 1944 Feb; 79(2):197-203. PubMed ID: 19871363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing points-based risk-scoring systems in the presence of competing risks.
    Austin PC; Lee DS; D'Agostino RB; Fine JP
    Stat Med; 2018 Apr; 37(8):1405. PubMed ID: 29529711
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.